Table 5.
Collaborations/partnerships between companies interviewed and foreign entities
| Company name | Collaborations and their objectives |
|---|---|
| Amoytop Biotech | Marketing contract with Ranbaxy Pharmaceuticals (Haryana, India) to market granulocyte colony stimulating factor (G-CSF) drug in India. |
| Beijing Wantai Biological Pharmacy Enterprise | Deal to distribute Bio-Rad Laboratories' (Hercules, CA, USA) products in China. Funding obtained from KPCB Risk Management Fund (Menlo Park, CA, USA) to develop antibody therapies against avian influenza. Partnership with University of Georgia (Athens, GA, USA) to develop rabies diagnostics. |
| Bio-Bridge Science | Exclusive out-license of papillomavirus pseudovirus technology to Loyola University (Chicago). |
| CapitalBio | Joint R&D and commercialization programs in China with Affymetrix (Santa Clara, CA, USA) for gene expression profiling and genotyping services (including the development of an advanced GeneChip-compatible point-of-care system) using Affymetrix's photolithographically synthesized oligonucleotide chip technology. Provided non-exclusive rights to Alpha Innotech (San Leandro, CA, USA) for marketing of CapitalBio's microarray laser scanner. Deal to undertake joint product development, manufacturing in China, technology transfer, services and products mutual representation with BioTools (Madrid). Deal to distribute Becton Dickinson (Franklin Lakes, NJ, USA) products in China. Exclusive rights to distribute certain products from Enzo Biochem (New York), BioMachines (Research Triangle Park, NC, USA), Aviva Systems Biology (San Diego), Macherey-Nagel (Düren, Germany), Advalytix (Brunnthal, Germany) in China. Exclusive rights to MediBic (Tokyo) to market CapitalBio's pharmacogenomic services in Japan. Exclusive rights to distribute certain CapitalBio products given to Greenmate Biotech (Seoul, Korea) in Korea, FK Biotec (Port Alegre, Brazil) in Brazil and VitroLab (Istanbul, Turkey) in Turkey. Nonexclusive distribution rights to certain CapitalBio products provided to TechnoConcept (New Delhi, India) and Viswagen Biotech (Kerala, India) in India and Australian Biosearch (Karrinyup, Australia) in Australia. |
| HD Biosciences | Codevelopment of functional assays for several identified GPCRs and ion channels with Organon. Under a nondisclosure agreement, undertaking assay development and hit-to-lead solution for GPCR and kinase targets with two major Western pharmaceutical companies. Cooperation agreement to develop GPCR screening models with Novasite Pharmaceuticals (San Diego). |
| Shanghai Genomics | Research collaboration to identify more selective nuclear receptor modulators with Organon initially to last for two years. Another research collaboration with Centocor (Malvern, PA, USA) to understand inflammatory signaling pathways, initially to last for a period of one-and-a-half years. Contract with Roche or undisclosed research. |
| Shanghai Genon Bio-Engineering | R&D partnership with Tori University (Tori, Japan) and Babraham Institute (Cambridge, UK). |
| Shanghai Huaguan Biochip | In-license of Luminex (Austin, TX, USA) xMAP technology for genotyping human papilloma virus. |
| Shenzhen Beike Biotechnologies | Research collaboration with Imperial College (London) on bioreactor technology. |
| Shenzhen Chipscreen Biosciences | License and codevelopment agreement with HUYA Bioscience International (San Diego) relating to chidamide, a histone deacetylase inhibitor for the treatment of cancer currently in phase 1 trials in China. Under the terms of the deal, HUYA acquires worldwide rights to the agent, excluding China, in return for co-developing the agent through phase 1 evaluation. HUYA plans to file an Investigational New Drug application with the US FDA and to begin phase 1 trials of the agent in the USA and Europe. Service orientated contract with Roche. Codeveloped microarray data management and analysis software (ArrayTrack) with National Center for Toxicological Research (Jefferson, AR, USA). Research partnership with Ludwig Institute (New York). |
| SiBiono GeneTech | Codevelopment agreement with DNAVEC (Ibaraki, Japan) for DNA therapeutic vaccine for AIDS. |
| SinoGenoMax | Research agreement with Tulane University (New Orleans). |
| Sinovac Biotech | Agreement to market LG Life Sciences' (Seoul) HBV vaccines in China. Exclusive distribution deal with Glovax CV, a Dutch biopharmaceutical company with operations in Mexico, to distribute Sinovac's vaccine products in Mexico. Comarketing and promotion agreement with GlaxoSmithKline (China) Investment Co. Ltd. (Beijing). for Sinovac's seasonal influenza vaccine Anflu. |
| Shanghai Sunway Biotech | Exclusive worldwide license for Onyx Pharmaceuticals' (Emeryville, CA, USA) Onyx-015 oncolytic adenovirus against head-and-neck cancer. |
| Starvax International | Agreement to co-develop Mologen's (Berlin) double stem loop immunomodulators (oligonucleotides with phosphorodiester backbones and a dumbbell-like structure, each loop containing CG motifs) as cancer therapeutics. |
| Tianjin SinoBiotech | LifeCord (Seoul) has made financial investments in Tianjin SinoBiotech. Research partnership with Temple University (Philadelphia). FortuneRock (Baltimore) is the US-based parent company of Tianjin SinoBiotech, which was started by the same founder, and shares intellectual property with Tianjin SinoBiotech. |
| Wuxi PharmaTech | Services provided to >65 pharmaceutical and biotech customers, including nine of the top ten pharmaceutical companies in 2006. |